A review of the therapeutic potential of the cysteinyl leukotriene antagonist Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic-stem cell transplantation and its possible mechanisms

Lung and hematopoietic stem cell transplantation are therapeutic modalities in chronic pulmonary and hematological diseases, respectively. One of the complications in these patients is the development of bronchiolitis obliterans syndrome (BOS). The efficacy and safety of available treatment strategi...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic advances in respiratory disease 2024-01, Vol.18, p.17534666241232284-17534666241232284
Main Authors: Kordjazy, Nastaran, Amini, Shahideh
Format: Article
Language:English
Subjects:
Acetates
Bronchiolitis Obliterans - diagnosis
Bronchiolitis Obliterans - drug therapy
Bronchiolitis Obliterans - etiology
Bronchiolitis Obliterans Syndrome
Cyclopropanes
Graft vs Host Disease - drug therapy
Graft vs Host Disease - etiology
Hematopoietic Stem Cell Transplantation - adverse effects
Humans
Leukotriene Antagonists - adverse effects
Leukotrienes - pharmacology
Leukotrienes - therapeutic use
Lung
Lung Transplantation - adverse effects
Quinolines
Review
Sulfides
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung and hematopoietic stem cell transplantation are therapeutic modalities in chronic pulmonary and hematological diseases, respectively. One of the complications in these patients is the development of bronchiolitis obliterans syndrome (BOS). The efficacy and safety of available treatment strategies in BOS remain a challenge. A few mechanisms have been recognized for BOS in lung transplant and graft- -host disease (GVHD) patients involving the TH-1 and TH-2 cells, NF-kappa B, TGF-b, several cytokines and chemokines, and cysteinyl leukotrienes (CysLT). Montelukast is a highly selective CysLT receptor antagonist that has been demonstrated to exert anti-inflammatory and anti-fibrotic effects in abundant experiments. One area of interest for the use of montelukast is lung transplants or GVHD-associated BOS. Herein, we briefly review data regarding the mechanisms involved in BOS development and montelukast administration as a treatment modality for BOS, and finally, the possible relationship between CysLTs antagonism and BOS improvement will be discussed.
ISSN:1753-4666
1753-4658
1753-4666
DOI:10.1177/17534666241232284